Re: Zenith Epigenetics is proud to announce the appointment Dr. Brad Thompson, PhD to our Board of Directors!
posted on
Feb 07, 2022 12:37PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
"Perhaps this appointment is a hint that shareholder liquidity is in the works?"
Its well past time IMO!